What's Happening?
The Lustgarten Foundation, the largest private funder of pancreatic cancer research, recently convened its Scientific Advisory Board (SAB) to establish the strategic direction for the next generation of pancreatic cancer treatments. Following a year of significant
scientific progress, including the FDA approval of the RAS-targeted therapy RASONQUE™ (daraxonrasib), the meeting focused on building upon these breakthroughs to develop more effective and durable treatments. Key areas of discussion included advancing methods to measure treatment response, understanding treatment failure and resistance, identifying new therapeutic targets and combinations, advancing prevention and interception strategies, and innovating clinical trial design. A central theme was the importance of integrating clinical observations, biological insights, and new methods for measuring treatment response to guide more personalized treatment strategies. The Foundation awarded $22.8 million in new research funding in fiscal year 2026, an $8.6 million increase from the previous year, supporting projects in early detection, therapeutics development, and personalized medicine.
Why It's Important?
The SAB's recommendations are crucial for guiding future investments and accelerating progress in pancreatic cancer research, a disease known for its aggressive nature and high mortality rate. By focusing on personalized treatment strategies and understanding resistance mechanisms, the Foundation aims to develop therapies that are more effective and tailored to individual patients, ultimately improving survival rates. The emphasis on innovating clinical trial design will help evaluate promising therapies more efficiently and identify patients most likely to benefit, speeding up the translation of discoveries into clinical practice. The increased funding demonstrates a strong commitment to tackling this challenging disease, supporting a wide range of research from early detection to advanced therapeutics. This strategic direction ensures that resources are directed towards the most promising scientific avenues, fostering collaboration and leveraging recent advancements in RAS-targeted therapies.
What's Next?
The Lustgarten Foundation will use the SAB's recommendations to guide its future funding decisions and research investments. This includes continued support for multi-institutional initiatives like the PASS (Pancreatic Adenocarcinoma Signature Stratification for Treatment) Consortium, which uses clinical trials to evaluate combination therapies and personalize treatment approaches. The Foundation will also continue to support efforts to overcome resistance to KRAS inhibitors and develop more effective treatment combinations, as well as projects focused on early detection of deadly cancers. Researchers will further explore new therapeutic targets and combination strategies, aiming to produce more durable responses in patients. The focus on innovative clinical trial designs will lead to more efficient evaluation of new therapies, with the goal of accelerating their translation into clinical practice and ultimately transforming pancreatic cancer into a curable disease.
Beyond the Headlines
The strategic direction set by the Lustgarten Foundation's SAB reflects a broader shift in cancer research towards precision medicine and a deeper understanding of tumor biology. The success of RAS-targeted therapies marks a significant milestone, opening new avenues for treatment that were once considered undruggable. However, the challenge of treatment resistance remains paramount, highlighting the need for continuous innovation in understanding disease progression at a molecular level. This collaborative approach, involving multiple institutions and experts, underscores the complexity of pancreatic cancer and the necessity of diverse perspectives to overcome it. The increased investment in research also signals a growing optimism within the scientific community that, with sustained effort and strategic funding, even the most recalcitrant cancers can be effectively managed, moving closer to the ultimate goal of a cure.
